Researchers sought an explanation for the paucity of research, drug development, and clinical trials focusing specifically on cancer in pediatric populations.
An international multidisciplinary panel of experts in pediatric oncology and infectious diseases convened to develop recommendations for the prevention and treatment of C difficile infection in pediatric patients with cancer or who are undergoing HSCT.
An increased risk of low educational attainment and attenuation in income at age 30 years has been observed in those that have experienced parental cancer.
Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.
Researchers accessed the SEER database and evaluated the population-based cancer survival data of 31,866 pediatric patients between the ages of 0 and 19.
A retrospective chart review was conducted to determine if adding lorazepam to granisetron would improve CINV prevention in pediatric patients with newly diagnosed ALL.
In a poster presentation at the 23rd Congress of EHA, researchers described a study of the efficacy of romiplastim in achieving a platelet response in pediatric patients with immune thrombocytopenia.
Children's Oncology Group study reported on the effect of dexrazoxane on cardiotoxicity of anthracycline-containing regimens in pediatric patients with AML at the 2018 ASCO Annual Meeting.
This fact sheet reviews cancer in adolescents and children, including possible causes, treatment, and the general outlook for childhood cancers.
Using the NEI-VFQ-25, researchers assessed vision-targeted health-related quality of life for survivors of retinoblastoma.
Researchers conducted a retrospective study to assess 18F-FDG PET/CT vs bone marrow biopsy to detect bone marrow involvement among pediatric patients with Hodgkin lymphoma.
A survey of oncology providers demonstrated a mix of opinions as to whether immunosuppressed children with cancer should attend school.
In a prospective study, researchers sought to determine the noninferiority of palonosetron to ondansetron in pediatric patients with cancer receiving moderate or high emetogenic chemotherapy.
Based on results of 2 prospective studies, the FDA approved the use of nilotinib in pediatric patients older than 1 year with newly diagnosed Ph+ CML-CP and those with TKI-intolerant or resistant disease.
Reintegration to the general environment, particularly to school, can be challenging for survivors of childhood cancers. This review discusses how adverse effects such as chemo brain may present extra challenges for these patients and what can be done to ease patients' anxiety.
Children who were hospitalized with pneumonia may be at higher risk of certain cancer types.
A previous single-site trial showed that patients with R/R B-cell ALL treated with tisagenlecleucel achieved high complete remission rates. In this study, investigators report on results after the scope of the study was expanded.
A retrospective study of data from POGONIS evaluated the effectiveness of specialized pediatric palliative care vs general palliative care or no palliative care in pediatric patients with cancer at the end of life.
A survey of pediatric oncology providers including physicians, nurses, and social workers reveals their willingness to consider medical marijuana for children with cancer, as well as their reasons against its use in these patients.
Research pinpointed clinical factors, such as headache, that may be associated with pediatric brain neoplasms.
Data presented at ASH 2017 illustrates the effectiveness of 2 prophylactic antiemetic regimens in pediatric patients receiving moderately or highly emetogenic chemotherapy.
Young patients with chronic ITP may experience relapse within 5 years of completing therapy. In this study, investigators sought to determine if the 4R+3Dex regimen for chronic ITP would improve response rates in pediatric patients with the disease.
Improved survival in pediatric patients with standard-risk ALL has shifted the focus toward reducing treatment burden and toxicity; therefore, researchers sought to determine the effects of reduced DI chemotherapy on relapse and survival.
US FDA approval of dasatinib is extended to pediatric patients with Ph+ CML based on data from 2 open-label, nonrandomized trials involving 97 patients.
In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.
Risk of developing cancer as a result of childhood exposure to medical imaging radiation is not increased in children or adults, a new study reports.
The Pediatric Cancer Working Group of the AACR released its first consensus screening guidelines for children with common cancer predisposition syndromes.
Children and adolescent patients with cancer are able to accurately report subjective adverse events (AEs) they experience during their cancer treatment, and they are willing to do so.
The medications so far show little efficacy in children with cancer, but new studies may provide clues to how to change this, pediatric oncologist says.
Sign Up for Free e-newsletters
- Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study
- CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma
- New Method Estimates Risk for Breast Cancer Recurrence
- Molecular Features May Predict Response in Primary Pancreatic Cancer
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Counseling Patients on Oral Chemotherapy
- Patients and Caregivers Worry About Cost of Cancer Care
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Head and Neck Cancer Survivors Have Increased Suicide Risk
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|